Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome
Stroke · 2025-04 · 56 (4) · 838-847
DOI: 10.1161/strokeaha.124.050131 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Stroke, 2025-04. Verfasst von Chloe A Mutimer und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (C.A.M., H.Z., L.C., B.C.V.C., V.Y., G.S., G.A.D., S.M.D…. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Hematoma, Tranexamic Acid. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: UNIMELB | Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne.
Abstract (Originalsprache)
BACKGROUND: There are limited data on ultra-early hematoma growth dynamics and their clinical impact in primary intracerebral hemorrhage (ICH). We aimed to estimate the incidence of hematoma expansion within the hyperacute period of ICH, describe hematoma dynamics over time, investigate the associations between ultra-early hematoma expansion and clinical outcomes after ICH, and assess the effect of tranexamic acid on ultra-early hematoma expansion. METHODS: We performed a preplanned secondary analysis of the STOP-MSU trial (Stopping Intracerebral Hemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units), which compared tranexamic acid with placebo in 201 patients with primary ICH presenting within 2 hours of symptom onset. Repeat computed tomography imaging ≈1 hour after treatment commencement was encouraged (ultra-early reimaging), and patients with this imaging were included in this descriptive study. Imaging analyses were separated into the following time epochs: baseline—the period from onset-to-baseline imaging; ultra-early—the period from baseline imaging to ultra-early reimaging; and interval—the period from ultra-early reimaging to 24-hour reimaging. Hematoma expansion was defined as a ≥33% or ≥6 mL increase from baseline, and functional outcomes were assessed at 90 days (poor functional outcome defined as modified Rankin Scale score of 3–6) using unadjusted logistic regression models. RESULTS: We included 105 patients who had ultra-early reimaging (median age, 66 years; 40% female). Median onset-to-baseline imaging time was 74 minutes (interquartile range, 56–87 minutes), and baseline-to-ultra-early reimaging time was 95 minutes (interquartile range, 74–132 minutes). Forty-one patients (39%) had ultra-early hematoma expansion. These patients had larger baseline hematomas (15.9 mL versus 9.1 mL, P =0.03) compared with those with no early hematoma expansion. Hematoma growth rate declined over time (clustered median regression P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital (C.A.M., H.Z., L.C., B.C.V.C., V.Y., G.S., G.A.D., S.M.D., N.Y.), University of Melbourne, Parkville, Victoria, Australia.
- Department of Neurology, Christchurch Hospital, New Zealand (T.Y.W.).
- Department of Medicine, University of Otago, Christchurch, New Zealand (T.Y.W.).
- Melbourne Medical School (L.C.), University of Melbourne, Parkville, Victoria, Australia.
- Department of Interventional Neuroradiology, Liverpool Hospital, New South Wales, Australia (A.C.).
- Department of Neurology, Helsinki University Hospital, Finland (A.M.).
ORCID-Profile: Chloe A Mutimer, Teddy Y Wu, Henry Zhao, Leonid Churilov, Bruce C V Campbell, Andrew Cheung, Atte Meretoja, Timothy J Kleinig, Philip M Choi, Geoffrey C Cloud, Rohan Grimley, Darshan Shah, Annemarei Ranta, Karim Mahawish, Vignan Yogendrakumar, Geoffrey A Donnan, Stephen M Davis, Nawaf Yassi
Förderung
- UNIMELB | Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne
Zitieren
APA
Mutimer, C. A., Wu, T. Y., Zhao, H., Churilov, L., Campbell, B. C. V., Cheung, A., Meretoja, A., Kleinig, T. J., Choi, P. M., Ma, H., Cloud, G. C., Grimley, R., Shah, D., Ranta, A., Mahawish, K., Yogendrakumar, V., Sharma, G., Donnan, G. A., Davis, S. M., …, & STOP-MSU Trial Investigators (2025). Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome. Stroke, 56(4), 838-847. https://doi.org/10.1161/strokeaha.124.050131
Vancouver
Mutimer CA, Wu TY, Zhao H, Churilov L, Campbell BCV, Cheung A, et al. Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome. Stroke. 2025;56(4):838-847. doi:10.1161/strokeaha.124.050131
BibTeX
@article{Mutimer2025,
author = {Mutimer, Chloe A and Wu, Teddy Y and Zhao, Henry and Churilov, Leonid and Campbell, Bruce C V and Cheung, Andrew and Meretoja, Atte and Kleinig, Timothy J and Choi, Philip M and Ma, Henry and Cloud, Geoffrey C and Grimley, Rohan and Shah, Darshan and Ranta, Annemarei and Mahawish, Karim and Yogendrakumar, Vignan and Sharma, Gagan and Donnan, Geoffrey A and Davis, Stephen M and Yassi, Nawaf and STOP-MSU Trial Investigators, STOP-MSU Trial Investigators},
title = {Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome},
journal = {Stroke},
year = {2025},
volume = {56},
number = {4},
pages = {838--847},
doi = {10.1161/strokeaha.124.050131}
}
EUVIMED